Nebivolol hydrochloride(CAS:152520-56-4)

Nebivolol Hydrochloride, CAS 152520-56-4, is a representative API of third-generation highly selective β1 receptor blockers. It overcomes the inherent defects of first and second-generation beta blockers, which only suppress sympathetic nerves and easily cause peripheral vasoconstriction, cold extremities and fatigue. Thanks to its unique dual pharmacological activity, it has become a core raw material for global high-end cardiovascular drug research and clinical chronic disease treatment. This compound owns stable chemical structure, controllable chiral purity and strict impurity limits, fully complying with pharmacopoeia standards worldwide. It can be manufactured into common oral tablets and sustained-release formulations, meeting the demands of high-end preparation production, generic drug development and international export business.

In terms of pharmacological mechanism, Nebivolol Hydrochloride acts through two synergistic pathways. First, it selectively blocks cardiac β1 adrenergic receptors, strongly inhibits overactivated sympathetic nerve system, reduces resting and exercise heart rate, weakens myocardial contraction and lowers myocardial oxygen consumption to relieve myocardial ischemia. It also suppresses renin secretion and inhibits RAAS activity to achieve basic antihypertensive efficacy. Second, it features exclusive endothelium-dependent vasodilating capacity: it stimulates endothelial cells to synthesize and release nitric oxide (NO), relaxes vascular smooth muscle and dilates peripheral arteries to reduce systemic vascular resistance. The combination of two mechanisms avoids the side effect of elevated peripheral resistance seen in conventional beta blockers, delivering smooth blood pressure reduction without cold limbs or intermittent claudication. It barely binds to β2 receptors on bronchi and skeletal muscles, so patients with asthma or COPD complicated with hypertension can take it safely with wider applicable crowds.

Clinically, Nebivolol Hydrochloride is mainly applied in long-term management of mild and moderate primary hypertension. Monotherapy achieves stable 24-hour blood pressure control, showing prominent curative effect for young and middle-aged patients with sympathetic excitement hypertension and elderly isolated systolic hypertension. Combined with calcium channel blocker and ACEI APIs, it generates synergistic efficacy, lowers single drug dosage and reduces risks of adverse reactions. Meanwhile, it serves as a standard therapeutic raw material for chronic systolic heart failure. Long-term administration reverses ventricular hypertrophy, relieves cardiac load, alleviates endothelial injury, improves patients’ exercise tolerance and cuts the long-term incidence of cardiovascular events. Different from metoprolol and bisoprolol, it produces no negative influence on lipid and glucose metabolism, suitable for long-term medication of hypertensive patients complicated with diabetes and hyperlipidemia.

Regarding safety and industrial production, Nebivolol Hydrochloride has a wide therapeutic window with extremely low incidence of adverse reactions under routine doses. Bradycardia, fatigue and gastrointestinal discomfort rarely occur, bringing far better tolerance than classic beta blockers. Mature synthetic technology guarantees stable batch quality, uniform purity and low impurities with controllable mass production costs, leading to sustained bulk purchasing demands from pharmaceutical manufacturers globally. Possessing four core advantages including targeted cardiac blockage, NO-mediated vasodilation, endothelial protection and neutral effect on glucose-lipid metabolism, Nebivolol Hydrochloride, as a differentiated new-generation antihypertensive API, holds irreplaceable competitiveness in high-end cardiovascular preparations, combined chronic disease medication and innovative drug R&D, with promising and stable market prospects.